Ali, Amar
,
Bain, Steve
Hicks, Debbie
Newland Jones, Phillip
Patel, Dipesh C.
Evans, Marc
Fernando, Kevin
James, June
Milne, Nicola
Viljoen, Adie
Wilding, John http://orcid.org/0000-0003-2839-8404
Funding for this research was provided by:
Napp Pharmaceuticals Limited
Article History
Received: 9 May 2019
First Online: 9 July 2019
Change Date: 18 July 2019
Change Type: Correction
Change Details: In the original publication, Table 2 note was incorrectly published as “SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m<Superscript>2</Superscript>. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m<Superscript>2</Superscript>”.